Profile
Robert A.
Reed formerly worked at Merck & Co., Inc., as Director-Pharmaceutical Research & Development, Imunon, Inc., as Executive Director, VP-CMC & Technical Operations from 2012 to 2013, Jefferson-Pilot Corp., as Vice President, Aradigm Corp., as Vice President-CMC, Regulatory & Quality, Reata Pharmaceuticals, Inc., as Chief Technical Officer & Senior VP-CMC, and XenoPort, Inc., as Vice President-Pharmaceutical Operations in 2009.
Dr. Reed received his doctorate degree from The University of North Carolina at Charlotte.
Former positions of Robert A. Reed
| Companies | Position | End |
|---|---|---|
| XENOPORT, INC. | Corporate Officer/Principal | 2008-12-31 |
| Jefferson-Pilot Corp. | Corporate Officer/Principal | 2006-04-04 |
| REATA PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | - |
| MERCK & CO., INC. | Corporate Officer/Principal | - |
| ARADIGM CORPORATION | Corporate Officer/Principal | - |
Training of Robert A. Reed
| The University of North Carolina at Charlotte | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 2 |
|---|---|
| MERCK & CO., INC. | Health Technology |
| IMUNON, INC. | Health Technology |
| Private companies | 4 |
|---|---|
| Jefferson-Pilot Corp. | Finance |
Aradigm Corp.
 Aradigm Corp. Pharmaceuticals: MajorHealth Technology Aradigm Corp. was a pharmaceutical company, which was focused on the development and commercialization of drugs delivered by inhalation for the prevention and treatment of severe respiratory diseases by pulmonologists. The company was founded in 1991 and was headquartered in Hayward, CA. | Health Technology |
Reata Pharmaceuticals, Inc.
 Reata Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Reata Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in identifying, developing, and commercializing pharmaceutical products. Its product candidates are bardoxolone methyl and omaveloxolone, which activate the transcription factor Nrf2 to restore mitochondrial function, reduce oxidative stress, and resolve inflammation. The company was founded by J. Warren Huff in 2002 and is headquartered in Plano, TX. | Health Technology |
XenoPort, Inc.
 XenoPort, Inc. Pharmaceuticals: MajorHealth Technology XenoPort, Inc. operated as a biopharmaceutical company. Its products included horizant and regnite. The company was founded by Ronald W. Barrett, William J. Dower and Mark A. Gallop on December 17, 1999 and was headquartered in Atlanta, GA. | Health Technology |
- Stock Market
- Insiders
- Robert A. Reed
